Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

Novo Nordisk A/S, GE HealthCare Technologies Inc. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...

S&P 500 futures steady after record highs. Novo Nordisk and Twilio surge, while Boeing posts $4B loss. Traders eye Fed policy ...

As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...

The microbial ecosystems within our mouths may affect our cognitive function as we age, according to a study. Interventions such as prebiotics, including dietary nitrate, have potential for delaying ...

Socially responsible companies are businesses that integrate social and environmental considerations into their core operations and decision-making processes.

Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 ...

In the trial, patients who received a once-weekly 20 mg injection of amycretin over 36 weeks saw an impressive 22% reduction ...